Company profile


Novaremed is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain. Novaremed was founded in Israel in 2008, where development work was done up to a successful Phase IIa Proof of Concept (PoC) study in Diabetic Neuropathic Pain (DNP). In 2017, Novaremed moved from Israel to Basel, Switzerland, which is one of the most important biotech and pharma clusters in Europe. This relocation allowed the company to gain access to experienced clinical development staff and services and investor capital. Novaremed is currently preparing for a global Phase IIb study in DNP.

Source: startup.ch

More news about Novaremed

29.10.2018 08:50

Novaremed gets closer to ambition

Please login or
register to use the
bookmark feature

By continuing to use this website you agree with our TERMS AND CONDITIONS